News
  • Area B2 of Ronghua Mountain Industrial Group (GanoHerb Industrial Park), Pucheng County, Nanping City, Fujian province

  • +86-591-83053386

COMPANY NEWS
HOME > NEWS >
Ganoderic acid C1 is antiasthmatic by inhibiting TNF-α production
2021-09-15   Source:ganodermanews.com    Hit:63   Font: 
August 1, 2015 / Icahn School of Medicine at Mount Sinai / International Immunopharmacology

Complied by Wu Tingyao

 
 
Asthma is a disease caused by allergen-induced inflammation of the respiratory tract. This inflammatory response is mainly initiated by the cytokine secreted by Th2 (type 2 T cells), and then relayed by TNF-α, which has nothing to do with Th2, so that the inflammatory response continues.

For the asthmatic inflammatory response mediated by TNF-α, the use of inhaled corticosteroid (ICS) is usually ineffective - ICS is the first-line treatment recommended by the Global Initiative for Asthma for children with mild asthma. Therefore, how to effectively inhibit TNF-α in the first time has become one of the essentials for the treatment of asthma.

In May 2015, a study published by Icahn School of Medicine at Mount Sinai in the United States pointed to the single triterpenoid component in Ganoderma lucidum, ganoderic acid C1. The report pointed out that the formula ASHMTM, which is composed of three Chinese medicinal water extracts including Ganoderma lucidumSophora flavescens and Glycyrrhiza uralensis, is effective and highly safe for asthma patients.

They have previously demonstrated through asthma model mice that this Chinese medicine formula can inhibit Th2 and TNF-α-related inflammatory reactions, and pointed out that Glycyrrhiza uralensis is a key component to inhibit Th2-related inflammatory reactions. Now, they have confirmed that it is Ganoderma lucidum, not the other two traditional Chinese medicine extracts, which inhibited the release of TNF-α from mouse macrophages, and it is the triterpene-rich methylene chloride extract from Ganoderma lucidum (instead of polysaccharides) that plays this role.

The methylene chloride extract was further divided into 15 components, and it was found that only ganoderic acid C1 can effectively inhibit mouse macrophages and asthma patients' peripheral blood mononuclear cells from releasing TNF-α. The mechanism of action is mainly from regulating the expression of NF-κB molecules in cells and blocking part of the signaling pathways related to MAPK and AP-1.

At about the same time, the research team published a report in another international journal stating that ganoderic acid C1 can regulate NF-κB-related signaling pathways and reduce the inflammatory response caused by Crohn's disease; Now it has been proved that ganoderic acid C1 may improve asthma by inhibiting the secretion of TNF-α. The anti-inflammatory potential of ganoderic acid C1 cannot be ignored.

[Source] Liu C, et al. 2015. 
Ganoderic acid C1 isolated from the anti-asthma formula, ASHMI™ suppresses TNF-α production by mouse macrophages and peripheral blood mononuclear cells from asthma patients. Int Immunopharmacol. 2015 Aug;27(2):224-31.

 
 END
 
About the author/ Ms. Wu Tingyao
Wu Tingyao has been reporting on first-hand Ganoderma information since 1999. She is the author of Healing with Ganoderma (published in The People's Medical Publishing House in April 2017). 
 
★ This article is published under the exclusive authorization of the author. ★ The above works cannot be reproduced, excerpted or used in other ways without the authorization of the author. ★ For violations of the above statement, the author will pursue relevant legal responsibilities. ★ The original text of this article was written in Chinese by Wu Tingyao and translated into English by Alfred Liu. If there is any discrepancy between the translation (English) and the original (Chinese), the original Chinese shall prevail. If readers have any questions, please contact the original author, Ms. Wu Tingyao.
      
GanoHerb   |   Xianzhilou   |   Sitemap   |   About us   |   Contact us
Copyright  ©2019 Fujian Xianzhilou Nutra-Industry CO.,LTD     闽ICP备17009144号
contact